Merck & Co. Inc.

05/04/2026 | Press release | Distributed by Public on 05/04/2026 16:28

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Maraldo David R.
2. Date of Event Requiring Statement (Month/Day/Year)
05/01/2026
3. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [MRK]
(Last) (First) (Middle)
126 EAST LINCOLN AVENUE
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP & Pres. MMD
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
RAHWAY, NJ 07065
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 17,819.434 D
Common Stock - 401(k) Plan 8,359.14 I By 401 (k)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit 05/02/2024(1) 05/02/2026 Common Stock 552 (2) D
Restricted Stock Unit 04/30/2025(3) 04/30/2027 Common Stock 581 (2) D
Restricted Stock Unit 04/29/2026(4) 04/29/2028 Common Stock 2,361 (2) D
Stock Option (Right to Buy) 05/04/2022(5) 05/03/2031 Common Stock 9,465 $73.73 D
Stock Option (Right to Buy) 05/03/2023(6) 05/02/2032 Common Stock 9,709 $87.1 D
Stock Option (Right to Buy) 05/02/2024(7) 05/01/2033 Common Stock 8,990 $117.89 D
Stock Option (Right to Buy) 04/30/2025(8) 04/29/2034 Common Stock 8,789 $129.22 D
Stock Option (Right to Buy) 04/29/2026(9) 04/28/2035 Common Stock 8,060 $84.71 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Maraldo David R.
126 EAST LINCOLN AVENUE
RAHWAY, NJ 07065
EVP & Pres. MMD

Signatures

/s/ Kelly E. W. Grez as Attorney-in-Fact for David Maraldo 05/04/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025,and 5/2/2026.
(2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
(3) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026, and, 4/30/2027.
(4) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027, and, 4/29/2028.
(5) The options became exercisable in equal installments in on 5/4/2022, 5/4/2023, and 5/4/2024.
(6) The options became exercisable in equal installments in on 5/5/2024, 5/5/2025, and 5/5/2026.
(7) The options vest and become exercisable in equal installments on 5/2/2024, 5/2/2025, and 5/2/2026.
(8) The options vest and become exercisable in equal installments on 4/30/2025, 4/30/2026, and 4/30/2027.
(9) The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Merck & Co. Inc. published this content on May 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 04, 2026 at 22:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]